Search
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnSuch combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16]. … Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigational[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. … [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over t...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseVadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnInterferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology.
Quetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalIt is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].[A2189]
Categories: Antidepressive Agents Indicated for DepressionGaradacimab
go.drugbank.com/drugs/DB15629Approved[A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Capreomycin
go.drugbank.com/drugs/DB00314ApprovedInvestigationalCyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisPipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnAmong the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. … It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.